GGrantIndex
Sort

53,477 grants matching addiction

Researching Effective Strategies to Prevent Opioid Death (RESPOND)

$716,684
Benjamin P Linas · Boston Medical Center · R01 · FY2020 · DA

Pharmacologically-based Strategies for Buprenorphine Treatment During Pregnancy

$716,681
Steve N Caritis · Magee-Women'S Res Inst And Foundation · R01 · FY2018 · HD

Gabapentin Treatment of Cannabis Dependence

$716,618
Barbara J Mason · Scripps Research Institute, The · R01 · FY2011 · DA

Data Driven Strategies for Substance Misuse Identification in Hospitalized Patients

$716,603
Majid Afshar · University Of Wisconsin-Madison · R01 · FY2023 · DA

Enhancing Infrastructure for Clinical and Translational Research to Address the Opioid Epidemic

$716,466
Leslie A Lenert · Medical University Of South Carolina · U01 · FY2022 · TR

Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse

$716,442
Joan Weinberger Berman · Albert Einstein College Of Medicine · R01 · FY2021 · DA

Collaborative Care for Primary Care Patients with Alcohol Use Disorders

$716,432
Katharine Anthony Bradley · Kaiser Foundation Health Plan Of Washington · R01 · FY2012 · AA

Imaging sex differences in smoking-induced dopamine release via novel PET methods

$716,421
Evan D Morris · Yale University · R01 · FY2020 · DA

Epigenetic involvement in socio-emotional behavior studied by PET- MRI

$716,409
Nicole R Zurcher Wimmer · Massachusetts General Hospital · R01 · FY2023 · MH

Epigenetic involvement in socio-emotional behavior studied by PET- MRI

$716,409
Nicole R Zurcher Wimmer · Massachusetts General Hospital · R01 · FY2024 · MH

Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes

$716,226
Lauren M Slosky · University Of Minnesota · R01 · FY2024 · DA

Research Project 2 : Sweet and Cooling Flavors and Nicotine: Examinations in New and Established Tobacco Product Users

$716,165
Suchitra Krishnan-Sarin · Yale University · U54 · FY2021 · DA

Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)

$716,104
Mark P. McGovern · Stanford University · R01 · FY2021 · DA

Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trial

$716,100
Phillip O Coffin · Public Health Foundation Enterprises · R01 · FY2018 · DA

The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network

$716,028
Jose Szapocznik · University Of Miami School Of Medicine · UG1 · FY2019 · DA

A Novel Workflow to Screen for Illicit Drug Exposure in Newborns

$716,018
Rainer Ng · Baebies, Inc. · R44 · FY2020 · DA

Opioid Overdoses among Medicaid Beneficiaries: Predictors, Outcomes, and State Policy Effects

$716,003
Stephen Crystal · Rutgers, The State Univ Of N.J. · R01 · FY2019 · DA

Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults with AUD

$715,994
Michael G McDonell · Washington State University · R01 · FY2023 · AA

Regulation of Craving: Clinical Trial and Neural Mechanisms

$715,925
Hedy Kober · Yale University · R01 · FY2022 · AA

Studying How State and Local Health Services Delivery Policies can Mitigate the Effects of Disasters on Drug Addiction Treatment and Overdose: A Mixed-Methods Study of COVID-19.

$715,845
Matthew Eisenberg · Johns Hopkins University · R01 · FY2022 · DA

Advancing Communication Science to Reduce Disparities in Young Adult Cigar Use

$715,786
Adam O Goldstein · Univ Of North Carolina Chapel Hill · U54 · FY2023 · DA

Contributions of aberrant synaptic protein monoaminylation to opiate use disorder

$715,783
Ian S. Maze · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · DA

Provision of Drug Abuse Treatment Services Under Parity

$715,772
Constance M Horgan · Brandeis University · R01 · FY2012 · DA

Component 2: Administrative Core

$715,758
Robert O. Messing · Ernest Gallo Clinic And Research Center · P50 · FY2009 · AA

Non-opiate topical formulations for treating pain associated with molar extractions

$715,640
Alan Parr · Arcato Laboratories, Inc. · R44 · FY2022 · DE